ReviewFrontiers in neurology
Rewiring the seizing brain: stem cell grafts as neuromodulatory architects in epilepsy therapy.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neuroinflammation and Graft Survival in Pluripotent Stem Cell-Derived Therapies for the Central Nervous System.Journal of neurochemistry · 2026Review
- Advancements in Stem Cell Therapy for Managing Drug-Resistant Epilepsy.Molecular neurobiology · 2026Review
- Advancements in Stem Cell Therapy for Managing Drug-Resistant Epilepsy.Molecular neurobiology · 2026Review
- The Potential Protective Effects of EGCG Against Epilepsy-Induced Damage in Rats by Mitigating Oxidative Stress, Inflammation, and Apoptosis.Scientifica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an emerging therapeutic strategy, stem cell transplantation has demonstrated promising potential in the management of refractory epilepsy. Epilepsy, a prevalent neurological disorder characterized by recurrent seizures, affects approximately one-third of patients worldwide who exhibit resistance to existing antiepileptic drugs (AEDs). Consequently, exploring novel treatment modalities is imperative. Recent studies have indicated that stem cell transplantation improves neurological function in epilepsy through multiple mechanisms. Research has revealed that transplanted stem cells mitigate seizure-induced neuronal damage by replacing dead or dysfunctional neurons, secreting beneficial neurotrophic factors (e.g., brain-derived neurotrophic factor, BDNF), and releasing anti-inflammatory cytokines. Preclinical studies and early-phase clinical trials have shown that stem cell transplantation significantly reduces seizure frequency and enhances patients' quality of life. However, current research is limited by small sample sizes and short-term follow-ups, necessitating further validation of long-term efficacy. Despite its therapeutic promise, stem cell transplantation faces critical challenges. First, technical details such as the cell source, processing, method of transplantation, and timing have yet to be standardized, leading to potential variability in efficacy and safety across different stem cell types. Second, complications like immune rejection and tumorigenesis pose significant safety risks. Future research should focus on optimizing stem cell selection and processing, designing robust clinical trials to evaluate long-term safety and efficacy, exploring combinatorial approaches with existing therapies, and developing advanced biomaterials to enhance transplantation success. Additionally, monitoring post-transplant cell survival and functionality, along with identifying epilepsy-specific biomarkers, will be crucial to refining the precision and safety of stem cell-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.